Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head

NCT: NCT05706909 · ACTIVE_NOT_RECRUITING

NCT IDNCT05706909
StatusACTIVE_NOT_RECRUITING
Start Date2023-02-08
Completion2027-07

Brief Summary

The purpose of this study is to assess the clinical and x-ray results of patients who are treated with core decompression of the hip and the injection of a bone marrow concentrate and the use of the Bone Graft Substitute Genex®.

Frequently Asked Questions

What is The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head?

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head is a clinical trial registered under NCT05706909. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05706909?

The current status of NCT05706909 (The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head) is: ACTIVE_NOT_RECRUITING.

When did The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head start?

The Use of Genex in the Management of Early-Stage Osteonecrosis of the Femoral Head started on 2023-02-08.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑